Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00063297 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia
A Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT00063297 is a Phase 2 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 180 participants.
The verdict
NCT00063297, a Phase 2 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
This study is to determine the efficacy (how well the drug works), safety, and side effects of the study medication compared to placebo in the treatment of the negative symptoms of schizophrenia in adults.
Interventions
- DRUG R209130
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2003-05 |
| Est. Completion | 2003-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00063297
The ClinicalTrials.gov registry entry for NCT00063297 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which R209130 is the first listed.
NCT00063297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00063297 about?
NCT00063297 is a clinical study titled "Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia". This study is to determine the efficacy (how well the drug works), safety, and side effects of the study medication compared to placebo in the treatment of the negative symptoms of schizophrenia in adults.
What is the current status of trial NCT00063297?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2003-05. Estimated completion is 2003-10.
What interventions are being tested in trial NCT00063297?
The interventions under investigation include: R209130 (DRUG).
Who is sponsoring clinical trial NCT00063297?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.